Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RAD51C drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAD51C Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9/HEK293 expressed. |
View RAD51C Products |
| Gene Delivery | RAD51C Promise-ORF / Lentivirus Full-length ORF for stable cell lines and rescue assays. |
View RAD51C Products |
| Benchmark Ab | Anti-RAD51C Recombinant Antibody Recombinant positive control for expression and assay validation. |
View RAD51C Products |
| Validator | RAD51C siRNA Set For knockdown verification and synthetic lethality modeling. |
View RAD51C Products |
| Related Target A | PARP1 Synthetic lethality partner; key target in BRCA/RAD51C-deficient cancers. |
View PARP1 Products |
| Related Target B | ATR Synergistic pathway partner; inhibitor combinations overcome PARP resistance. |
View ATR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (BCDX2 Complex) | Full-length recombinant RAD51C with verified purity and theoretical MW for precise binding assays. |
| Resistance Mutation Screening | Customizable mutant recombinant proteins mimicking clinical reversion mutations. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live RAD51C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RAD51C therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule inhibitors targeting homologous recombination and synthetic lethality pathways. As first-generation therapies reach the clinic, the next wave of R&D is targeting drug-resistant reversion mutations and combination regimens with PARP or ATR inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Oncology-focused Biopharma | Breast & Ovarian Cancer | Protein-protein interaction (PPI) assays (Need high-purity RAD51C complex components) |
| Synthetic Lethality | AstraZeneca, GSK, Pfizer | HRD+ Solid Tumors | Gene knockdown and rescue validation (Need sequence-verified Lentivirus & siRNA) |
| Combination Therapies | Merck, Bayer | Refractory Cancers | Selectivity and cross-reactivity screening (Need recombinant PARP1, ATR, and BRCA2 proteins) |